Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Inclusion Criteria: * Adult subjects ≥18 to ≤55 years of age * Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm * Body mass index (BMI) ≥18 and ≤35 kg/sq m * Able and willing to provide written informed consent * Nonsmoker and has not used any tobacco products for at least 3 months prior to Screening * Willing to adhere to the prohibitions and restrictions specified in this protocol * Able to tolerate prolonged periods of quiet, motionless, supervised rest Exclusion Criteria: * Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 5 days of dosing * Use of any investigational agent or study treatment within 30 days prior to Screening * Use of any protein or antibody-based therapeutic agents within 3 months prior to Screening * Prior exposure to LX4211 * Daily use of cigarettes or any tobacco products within 3 months prior to Screening and while participating in the study * History of any major surgery within 6 months prior to Screening * History of any serious adverse reaction or hypersensitivity to any inactive component of LX4211 * History of renal disease or significantly abnormal kidney function tests * History of hepatic disease or significantly abnormal liver function tests * Women who are breastfeeding or are planning to become pregnant during the study * History of any active infection within 14 days prior to Screening * History of alcohol or substance abuse within 2 years prior to Screening * History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2 * Presence of clinically significant physical, laboratory, or ECG findings (eg, QTcF \>450 msec for females and QTcF \>430 msec for males) at Screening * \>30 premature ventricular beats per hour on the telemetry ECG monitoring at Day -2 of Period 1 * History of additional risk factors for the presence of a family history of Short QT Syndrome, Long QT Syndrome, sudden unexplained death at a young age (\<=40 years), drowning or sudden infant death syndrome in a first degree relative (ie, biological parent, sibling, or child) * Any skin condition likely to interfere with ECG electrode placement or adhesion * Any skin condition likely to interfere with ECG electrode placement or adhesion * Donation or loss of \>400 mL of blood or blood product within 3 months prior to Screening * Positive urine glucose during Screening * Positive pregnancy test during Screening * Positive urine screen for drugs of abuse during Screening * Positive urine test for alcohol during Screening * Inability or difficulty swallowing whole tablets or capsules * Unable or unwilling to communicate or cooperate with the Investigator for any reason